Squarepoint Ops LLC boosted its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT – Free Report) by 1,214.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 400,210 shares of the company’s stock after acquiring an additional 369,772 shares during the period. Squarepoint Ops LLC’s holdings in Health Catalyst were worth $796,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Visionary Wealth Advisors bought a new position in shares of Health Catalyst during the 2nd quarter valued at about $27,000. Hsbc Holdings PLC grew its holdings in Health Catalyst by 21.3% during the 1st quarter. Hsbc Holdings PLC now owns 98,868 shares of the company’s stock worth $123,000 after acquiring an additional 17,332 shares in the last quarter. Whetstone Capital Advisors LLC raised its holdings in Health Catalyst by 0.5% in the fourth quarter. Whetstone Capital Advisors LLC now owns 3,750,377 shares of the company’s stock worth $8,963,000 after purchasing an additional 19,027 shares in the last quarter. AXQ Capital LP acquired a new stake in Health Catalyst in the second quarter worth about $38,000. Finally, Williams & Novak LLC raised its stake in shares of Health Catalyst by 56.9% in the second quarter. Williams & Novak LLC now owns 53,607 shares of the company’s stock worth $107,000 after purchasing an additional 19,442 shares during the last quarter. 85.00% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
HCAT has been the subject of several recent research reports. Canaccord Genuity Group reaffirmed a “hold” rating and set a $1.80 target price (down from $3.00) on shares of Health Catalyst in a report on Thursday, August 20th. Citigroup reduced their price target on shares of Health Catalyst from $2.50 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Finally, Wells Fargo & Company decreased their target price on shares of Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating for the company in a research note on Thursday, August 13th. Three analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Health Catalyst has an average rating of “Hold” and a consensus target price of $2.45.
Health Catalyst Stock Performance
Health Catalyst stock opened at $1.77 on Friday. The company has a current ratio of 2.70, a quick ratio of 2.70 and a debt-to-equity ratio of 1.51. The firm has a market capitalization of $133.59 million, a P/E ratio of -0.48 and a beta of 1.53. The stock has a fifty day moving average price of $1.89 and a 200 day moving average price of $1.64. Health Catalyst, Inc. has a 52 week low of $0.96 and a 52 week high of $3.62.
Health Catalyst (NASDAQ:HCAT – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.01. The company had revenue of $70.49 million during the quarter, compared to the consensus estimate of $69.09 million. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.83%. Equities research analysts anticipate that Health Catalyst, Inc. will post -0.18 earnings per share for the current year.
Insiders Place Their Bets
In other Health Catalyst news, CEO Simeon Kohl bought 59,000 shares of the company’s stock in a transaction on Monday, September 14th. The shares were bought at an average cost of $1.79 per share, with a total value of $105,610.00. Following the completion of the acquisition, the chief executive officer owned 2,856,385 shares of the company’s stock, valued at approximately $5,112,929.15. This trade represents a 2.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 19.40% of the stock is currently owned by insiders.
Health Catalyst Profile
Health Catalyst, Inc is a healthcare technology and data analytics company that helps healthcare organizations use data to improve clinical outcomes, operational performance and financial results. The company provides software, data management capabilities and professional services designed to support hospitals, health systems, medical groups and other healthcare providers.
Its offerings include the Health Catalyst Data Operating System, which integrates and organizes data from disparate clinical, financial and operational systems, as well as analytics applications for areas such as quality improvement, population health, cost management and care delivery.
Featured Stories
- Five stocks we like better than Health Catalyst
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT – Free Report).
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
